Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9256 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GS-9256 | DRUG | 75 mg BID x 28 days |
| GS-9190 | DRUG | 40 mg BID x 28 days |
| Ribavirin | DRUG | 1000-1200 mg/day given BID |
| Peginterferon alfa-2a | DRUG | 180 ug q week |
Inclusion Criteria: * Adult subjects, ages 18-70 * Willing able to provide informed consent * BMI between 18 and 36 kg/m2 (inclusive) * Chronic HCV infection, genotype 1 * HCV RNA \>/= 3 log, but \< 7.2 log10 IU/ml at screen * Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis * ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
GS-9256 is an investigational small molecule being developed for the treatment of HCV Infection, specifically chronic hepatitis C virus infection. It is a Phase 2 investigational drug and is not yet approved for use.
GS-9256 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with HCV infection.
GS-9256 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
GS-9256 has been studied in one completed Phase 2 clinical trial, identified as NCT01072695. This trial evaluated GS-9256 in combination with GS-9190, with or without ribavirin, for 28 days in patients with chronic hepatitis C virus infection. The trial enrolled 46 participants across Belgium, France, Germany, and the United Kingdom.
No, GS-9256 is not the same as GS-9190. They are two distinct investigational drugs developed by Gilead Sciences. In the clinical trial NCT01072695, GS-9256 was studied alone and in combination with GS-9190, with or without ribavirin, to assess their effects in patients with chronic hepatitis C virus infection.